Navigation Links
Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
Date:6/13/2013

CAMBRIDGE, Mass., June 13, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled in a Phase 1/2 clinical trial of EPZ-6438 (E7438). The trial is designed to assess the safety, tolerability and pharmacokinetics of EPZ-6438 (E7438), an orally available, small molecule inhibitor for non-Hodgkin lymphoma patients who have a cancer-causing (oncogenic) point mutation in EZH2.

Epizyme is developing EPZ-6438 (E7438) in partnership with Eisai Co., Ltd. In April 2011, the two companies announced a worldwide partnership to discover, develop and commercialize therapeutics targeting EZH2, with Epizyme retaining an opt-in right to co-develop, co-commercialize and share profits with Eisai on licensed products in the United States. As a result of the first patient enrollment in this trial, Epizyme earned a $6 million milestone payment from Eisai.

About EZH2 Cancers

EZH2 is a histone methyltransferase (HMT) that can become oncogenic and cause non-Hodgkin lymphoma and solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are mainly associated with oncogenic EZH2 mutations. Currently, there are no therapies approved specifically for the treatment of non-Hodgkin lymphoma associated with an EZH2 point mutation.

About Epizyme, Inc.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of en
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Epizyme, Inc. Announces Pricing of Initial Public Offering
2. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Epizyme to Partner to Develop DOT1L Companion Diagnostic
4. Epizyme to Present at Upcoming Conferences in February
5. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
6. Barts Hospital, London enrolls first patients in ROX Medicals CONTROL-HTN resistant hypertension trial
7. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
8. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
9. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
10. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
11. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  By looking at the ... distinguish between two very different conditions that can ... Henderson , MD, PhD., a Denver ... this study can help the medical ... treatment options, for Post-Traumatic Stress Disorder (PTSD) and ...
(Date:5/4/2015)... , May 4, 2015   HeartWare International, Inc ... invasive, miniaturized circulatory support technologies that are revolutionizing the treatment ... Doug Godshall , is scheduled to present at the ... Las Vegas on Thursday, May 14, ... The live webcast of the Company,s presentation at the conference ...
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
Breaking Medicine Technology:New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
(Date:5/4/2015)... and Seattle, WA (PRWEB) May 04, 2015 ... formation of a collaboration to facilitate development of NM108, ... ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. ... MiDROPS™ formulation platform developed by EyeCRO, which can deliver ... via a topical eyedrop. , Under the terms ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Los ... now offering a more comfortable and attractive alternative for ... of choice for those who have lost teeth. Unfortunately, ... feel insecure or slip at the worst possible moment ... or talks. They can also painfully pinch or rub ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... in Charlottesville, VA. McCartney is one of the most ... this beloved performer continues to roll along with no signs ... legendary groups: Wings and The Beatles, has been celebrating his ... the “Out There” tour and has continually added new stops ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Ticket Down is ... the Colonial Life Arena in Columbia, South Carolina. ... continuation of his “Out There” tour which originally kicked off ... tour is North America and the legendary performer recently announced ... the Wells Fargo Arena on June 21st, in Charlottesville, VA ...
(Date:5/4/2015)... 04, 2015 New findings released today ... Association (ABTA) show that people diagnosed with a brain ... options, including clinical trials, at the time of diagnosis, ... difficult decisions about their course of treatment. The release ... first nationwide brain tumor volunteer network, the ABTA CommYOUnity™, ...
Breaking Medicine News(10 mins):Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... In a new report that bucks the concerns raised by ... Public Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are ... fight against tobacco-related diseases and death. The review, ... in the Journal of Public Health Policy , is ...
... set a target for the influenza vaccination rate for 2006 ... increase to more than 75% by 2010. These rates have ... In the current issue of Deutsches rzteblatt International ... group around Annicka M. Reuss presents rates from flu seasons ...
... , THURSDAY, Dec. 16 (HealthDay News) -- ... are treated with inhaled corticosteroids may face a significantly ... of diabetes, new Canadian research suggests. The warning ... 380,000 respiratory patients in Quebec. Inhaler use was associated ...
... The Simbiontes ("Symbionts" in English) Project brought together children, ... its kind fundraising project in Portugal. A true symbiosis ... this award for scientific research. Miguel Godinho Ferreira, ... outside Lisbon, is the first scientist to win the ...
... happy holiday thought, but an important one: The number of ... surges by 33 percent on New Year,s Day. The suspected ... by sociologist David Phillips of the University of California, San ... on New Year,s is published in the journal Addiction ...
... HealthDay Reporter , WEDNESDAY, Dec. 15 (HealthDay News) -- ... death diagnosis is not only unnecessary but may make it less ... organs, a new study finds. Researchers reviewed records from the ... children who had been declared brain dead. All of the people ...
Cached Medicine News:Health News:Evidence suggests e-cigs safer than cigarettes, researcher claims 2Health News:Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients 2Health News:Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients 3Health News:Instituto Gulbenkian de Ciencia scientist wins new Portuguese award Simbiontes for cancer research 2Health News:SIDS spikes on New Year's Day 2Health News:Second Brain Death Exam Unnecessary, Study Finds 2Health News:Second Brain Death Exam Unnecessary, Study Finds 3
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
... REMstar Plus with C-Flex ... controls, and the comfort of ... the REMstar Plus with C-Flex ... to deliver sleep therapy by ...
REMstar Pro with C-Flex is a combination of the advances from our other products. The difference is the C-Flex waveform which offers a more comfortable way to deliver sleep therapy by taking the work...
Low-taper wall construction guarantees error less than 1% absolute, 0.4 hematocrit, relative...
Medicine Products: